CN101411829A - Chinese medicinal composition for treating megrims and formulation thereof - Google Patents
Chinese medicinal composition for treating megrims and formulation thereof Download PDFInfo
- Publication number
- CN101411829A CN101411829A CNA2007101632070A CN200710163207A CN101411829A CN 101411829 A CN101411829 A CN 101411829A CN A2007101632070 A CNA2007101632070 A CN A2007101632070A CN 200710163207 A CN200710163207 A CN 200710163207A CN 101411829 A CN101411829 A CN 101411829A
- Authority
- CN
- China
- Prior art keywords
- vertigo
- chinese medicine
- medicine composition
- rhizoma
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a traditional Chinese medicine composition for treating vertigo and a preparation thereof. The traditional Chinese medicine composition consists of twelve bulk drugs such as radix astragali, hirudo, scorpion and the like, and all the drugs are used together to play a role of tonifying deficiency and activating venation, searching wind and reducing sputum, and stopping vertigo and benefiting marrow. Clinical studies show that the traditional Chinese medicine composition is effective in the treatment of the vertigo.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and preparation thereof for the treatment of vertigo, belong to the Chinese herbal and crude drugs preparations technical field.
Background technology
Vertigo is common clinical syndrome, and along with aged tendency of population, sickness rate increases day by day, being subjected to domestic and international medical matters circle extensively payes attention to, account for internal medicine emergency case's 5%, and the 81-91% of old outpatient service (Zhang Suzhen. the Clinics and Practices of vertigo. People's Medical Officer Press, 2001:1-2; 116-120; 238-240), patient's cause of disease of department of neurology and emergency department prescription on individual diagnosis is the most common with vertebral-basilar artery insufficiency.This disease is main and arteriosclerosis, hemodynamics change and cervical spondylosis is closely related, its basic pathology is changed to the vertebral-basilar artery disturbance of blood circulation and causes local brain tissue, especially organ of equilibration blood supply insufficiency (Sun Yan, Chen Mei, Huang Xiaoming etc. XINGNAOJING ZHUSHEYE is main treatment vertebral-basilar artery insufficiency 46 examples. the Zhejiang College Of Traditional Chinese Medicine journal, 2000,24 (2): 28-29).
Vertigo belongs to the dizzy category of the traditional Chinese medical science, its pathogenesis complexity, but conclude not exogenous wind, fire, expectorant, empty four aspects, " dizziness must be caused by phlegm " arranged then, " dizziness must be due to deficiency ", the argumentation of " calm do not do dizzy ", yet find often to have in the pathological process pathological phenomenon of venation block in clinical, meal with wine adds the collateral dredging medicine in the dialectical treatment, often receives the curative effect of getting twice the result with half the effort, think that dizzy pathogenesis is a deficiency of the liver and kindey, the weak brain network of deficiency of vital energy cervical carcinoma with cachexia, venation inanition in addition, weakened defensive QI, the heresy of wind-phlegm, taking advantage of a weak point in opponent's defence causes venation block into network, the impatency QI and blood, thus dizzy disease appears, it is main Therapeutic Principle that treatment is worked as with the tonify deficiency collateral dredging, and is assistant with the dispelling pathogenic wind and eliminating phlegm.
Dizzy is a kind of mobility or sensualness hallucination, and being body concerns that to space orientation and gravity body looks into the obstacle of ability, is sense of rotation, waves sense or levitation, is mainly caused by lost, vestibular nerve, brain stem and lesions on cerebellum.Be more common in middle-aged and elderly people, generally be divided into two types of peripheral vertigo and central vertigos clinically, wherein vertebral-basilar artery insufficiency (tremulous pulse, internal auditory artery, pontine arteries, the posterior cerebral artery ischemia that comprise cerebellum) be central vertigo commonly encountered diseases because of.Find by clinical research, the vertigo that medicine of the present invention is caused by vertebral-basilar artery insufficiency for treatment, clinical effectiveness is remarkable, the prevention of recurrence of controlling symptoms, and energy rapidly.
Summary of the invention
The invention provides a kind of Chinese medicine composition and preparation thereof for the treatment of vertigo.
The Radix Astragali, Hirudo activating qi and collateral are monarch drug in the medicine of the present invention; Rhizoma Chuanxiong, Scorpio, Radix Angelicae Sinensis, Fructus Corni promoting blood circulation to remove obstruction in the collateral are ministerial drug, Rhizoma Chuanxiong promoting blood circulation by removing wind wherein, and the up head is the gas medicine in the blood, Scorpio expel wind to dredge collateral, Chinese angelica blood supplementing and blood, the Fructus Corni YIN nourishing of enriching blood, beneficial marrow adds essence, and the monarch and his subjects are harmonious, and play the merit of benefiting QI for activating blood circulation collateral dredging altogether; The Rhizoma Atractylodis Macrocephalae, Poria, Pericarpium Citri Reticulatae, Caulis Bambusae In Taenia spleen invigorating dehumidifying are reduced phlegm, control living expectorant this, the Radix Achyranthis Bidentatae liver and kidney tonifying, helping enriches blood adds the power of essence, is adjuvant drug altogether; The Rhizoma Acori Graminei priming is up, and the opening or cleaning key is a messenger drug with logical brain network, and all medicines share, and play the tonify deficiency collateral dredging altogether, search air slaking expectorant, the merit of fixed dizzy beneficial marrow.
The invention provides a kind of Chinese medicine composition for the treatment of vertigo, it is characterized in that being making by the crude drug of following weight portion ratio:
Radix Astragali 30-50 Hirudo 2-5 Scorpio 2-5 Rhizoma Chuanxiong 6-12
Fructus Corni 6-12 Radix Achyranthis Bidentatae 6-15 Rhizoma Atractylodis Macrocephalae 6-15 Poria 12-40
Pericarpium Citri Reticulatae 6-12 Caulis Bambusae In Taenia 6-12 Radix Angelicae Sinensis 6-15 Rhizoma Acori Graminei 5-10
Preferably, Chinese medicine composition of the present invention is to be made by the crude drug of following weight portion ratio:
Radix Astragali 35-45 Hirudo 2-5 Scorpio 2-5 Rhizoma Chuanxiong 7-10
Fructus Corni 7-10 Radix Achyranthis Bidentatae 8-13 Rhizoma Atractylodis Macrocephalae 8-14 Poria 18-35
Pericarpium Citri Reticulatae 7-11 Caulis Bambusae In Taenia 6-12 Radix Angelicae Sinensis 6-13 Rhizoma Acori Graminei 5-10
More preferably, Chinese medicine composition of the present invention is to be made by the crude drug of following weight portion ratio:
The Radix Astragali 32 Hirudos 2.5 Scorpios 2.5 Rhizoma Chuanxiongs 7
Fructus Corni 7 Radix Achyranthis Bidentataes 7 Rhizoma Atractylodis Macrocephalaes 7 Poria 15
Pericarpium Citri Reticulatae 6.5 Caulis Bambusae In Taenia 6.5 Radix Angelicae Sinensis 7 Rhizoma Acori Graminei 6
Or make by the crude drug of following weight portion ratio:
The Radix Astragali 48 Hirudos 4.5 Scorpios 4.5 Rhizoma Chuanxiongs 11
Fructus Corni 11 Radix Achyranthis Bidentataes 14 Rhizoma Atractylodis Macrocephalaes 14 Poria 38
Pericarpium Citri Reticulatae 10.5 Caulis Bambusae In Taenia 11.5 Radix Angelicae Sinensis 13.5 Rhizoma Acori Graminei 9
Or make by the crude drug of following weight portion ratio:
The Radix Astragali 34 Hirudos 5 Scorpios 2.5 Rhizoma Chuanxiongs 11.5
Fructus Corni 6.5 Radix Achyranthis Bidentataes 14 Rhizoma Atractylodis Macrocephalaes 7 Poria 37
Pericarpium Citri Reticulatae 6.5 Caulis Bambusae In Taenia 11 Radix Angelicae Sinensis 7 Rhizoma Acori Graminei 8.5
Or make by the crude drug of following weight portion ratio:
The Radix Astragali 40 Hirudos 3.5 Scorpios 3.5 Rhizoma Chuanxiongs 9
Fructus Corni 9 Radix Achyranthis Bidentataes 10.5 Rhizoma Atractylodis Macrocephalaes 10 Poria 25
Pericarpium Citri Reticulatae 9 Caulis Bambusae In Taenia 9 Radix Angelicae Sinensis 10.5 Rhizoma Acori Graminei 7.5
The preparation formulation of Chinese medicine composition of the present invention is decoction, powder, capsule, pill or oral liquid.
The dosage form of Chinese medicine composition of the present invention adopts conventional preparation method preparation, and for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record makes the acceptable regular dosage form of pharmaceutics.
In the application of the present invention, described Chinese medicine composition is a kind of in decoction, powder, capsule, pill or the oral liquid formulations, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need when these dosage forms of preparation, to add acceptable other adjuvant of pharmacy (adjuvant of each dosage form record among the Fan Biting " pharmacy of Chinese materia medica ", Shanghai Science Press December in 1997 the 1st edition).
Preferably, the vertigo of traditional Chinese medicine composition for treating of the present invention is a megrim caused by vertebra-fundus artery blood supply insufficiency.
Preferably, the vertigo of traditional Chinese medicine composition for treating of the present invention is the cervical vertigo that circulatory disturbance causes.
Preferably, the vertigo of traditional Chinese medicine composition for treating of the present invention is the aural vertigo that circulatory disturbance causes.
Show through clinical trial, giving XIBILING JIAONANG (Xian-Janssen Pharmaceutical Ltd.'s production) treatment group in contrast, give medicine of the present invention and organize as treatment, is 78.50% for the total effective rate for the treatment of vertigo, obviously be better than 70.42% of matched group, have significant difference.
Show through clinical trial, give XIBILING JIAONANG (Xian-Janssen Pharmaceutical Ltd.'s production) treatment group in contrast, giving medicine of the present invention organizes as treatment, total effective rate for the treatment megrim caused by vertebra-fundus artery blood supply insufficiency is 83.33%, obviously be better than 76.92% of matched group, have significant difference.
Show through clinical trial, give XIBILING JIAONANG (Xian-Janssen Pharmaceutical Ltd.'s production) treatment group in contrast, giving medicine of the present invention organizes as treatment, total effective rate for the cervical vertigo that causes of treatment circulatory disturbance is 84.76%, obviously be better than 75.24% of matched group, have significant difference.
Show through clinical trial, give XIBILING JIAONANG (Xian-Janssen Pharmaceutical Ltd.'s production) treatment group in contrast, giving medicine of the present invention organizes as treatment, total effective rate for the aural vertigo that causes of treatment circulatory disturbance is 83.78%, obviously be better than 73.35% of matched group, have significant difference.
Be confirmation clinical drug curative effect of the present invention, the decoction that use prepares according to embodiment 1 described method (to call in the following text: medicine of the present invention) carried out following clinical observation:
1. data and method
1.1 case is selected
The diagnostic criteria of the transience vertebro-basilar artery insufficiency that proposes with reference to WHO and the diagnostic criteria (Lv Bingqing, clinical neurology) that domestic scholars proposes:
(1) morbidity more than 40 years old has repeated relapsing dizzy, and symptom obviously or aggravation when head or Body Position Change.
(2) morbidity anxious (taking place in 2 minutes).
(3) with the symptom and the Signs of one or more vertebral basilar system ischemic episodes, as nystagmus, walking shakiness, dysphagia, dysarthria, dysaudia etc., and transcranial doppler (TCD is hereinafter to be referred as TCD) prompting vertebro-basilar artery insufficiency.
(4) get rid of other with dizzy for main disease such as aural vertigo, cerebellum or hemorrhage of brain stem or infraction.
1.2 physical data
Observe case 56 examples altogether, the age is my the brain internal medicine inpatient of institute between 43-70 year, is divided into treatment group and matched group according to the sequencing of being in hospital according to the random number word table, and 30 examples are organized in treatment, male 14 examples, women 16 examples, average 55.18 ± 10.32 years old.Matched group 26 examples, male 12 examples, women 14 examples, average 55.41 ± 9.68 years old.Data such as two groups of sexes, age of onset, the state of an illness there are no significant difference (P〉0.05), have comparability.
1.3 Therapeutic Method
1.3.1 the treatment group is got the decoction 400ml of medicine of the present invention, early, late twice sub-service, and 2 weeks of the course of treatment.
1.3.2 matched group gives XIBILING JIAONANG (Xian-Janssen Pharmaceutical Ltd.'s production), each 5mg, every night 1 time oral, 2 weeks of the course of treatment.
1.4 observational technique
Observe the variation of cardinal symptoms before and after two groups of treatments (dizzy, headache is felt sick, vomiting, tinnitus, it is unclear to look the thing rotation, diplopia or extremity, facial numbness, the uncomfortable pain of neck), and write down the variation of TCD before and after dizzy degree, persistent period and the treatment.
1.5 criterion of therapeutical effect
With reference to " traditional Chinese medical science disease diagnosis criterion of therapeutical effect ".Divide 3 grades according to dizzy alleviation degree
(1) recovery from illness: ignore the thing rotation during conversion head position or rock the simultaneous phenomenon disappearance; The TCD blood flow rate is normal.
(2) take a turn for the better: ignore the thing rotation when static or rock, but can bring out and exist the part simultaneous phenomenon during conversion head position, the TCD blood flow rate is improved more than 50%.
(3) invalid: dizzy and simultaneous phenomenon does not have improvement, and the TCD blood flow rate is improved below 50%.
1.6 statistical method:
Measurement data is with (x ± s) expression adopts the t check, and enumeration data adopts the Ridit check.
2. result
2.1 two groups of clinical efficacies compare (table 1)
Table 1 liang group clinical efficacy is (example) relatively
| Group | n | Recovery from illness | Take a turn for the better | Invalid | Total effective rate | The time of dizzy disappearance (my god) |
| The treatment group | 30 | 9 * | 16 | 5 | 83.33％ * | 3.26±2.59 * |
| Matched group | 26 | 11 | 9 | 6 | 76.92％ | 5.45±3.01 |
Compare with matched group
*P＜0.05
The result shows that treatment group clinical efficacy obviously is better than matched group (P＜0.05), and dizzy extinction time is shorter than matched group (P＜0.05).
2.2 two groups of vertebral-basilar artery mean blood flow velocity change relatively (table 2)
Table 2 liang group vertebral-basilar artery mean blood flow velocity variation comparison (x ± s)
Relatively preceding with treatment:
*P＜0.05, with after the treatment of control group relatively: Δ P＜0.05
Before two groups of treatments vertebral-basilar artery blood supply mean flow raties relatively, difference there are no significant meaning (P〉0.05), two groups of each indexs of treatment back relatively, difference all has significance meaning (P＜0.05).
3, conclusion
Above clinical research shows that patient's symptom can be eliminated or alleviate to medicine of the present invention, and effect such as the vertebral-basilar artery of improvement blood flow rate is arranged, and is the active drug of treatment megrim caused by vertebra-fundus artery blood supply insufficiency.
The specific embodiment
Example below in conjunction with the preparation of medicine decoction of the present invention, powder, capsule, pill and oral liquid illustrates the specific embodiment of the present invention.
Embodiment 1:
The Radix Astragali 32 gram Hirudos 2.5 gram Scorpios 2.5 gram Rhizoma Chuanxiongs 7 grams
The Fructus Corni 7 gram Radix Achyranthis Bidentataes 7 gram Rhizoma Atractylodis Macrocephalaes 7 gram Poria 15 grams
Pericarpium Citri Reticulatae 6.5 gram Caulis Bambusae In Taenia 6.5 gram Radix Angelicae Sinensis 7 gram Rhizoma Acori Graminei 6 grams
Preparation method: formulation method is made decoction routinely.
Embodiment 2:
The Radix Astragali 48 gram Hirudos 4.5 gram Scorpios 4.5 gram Rhizoma Chuanxiongs 11 grams
The Fructus Corni 11 gram Radix Achyranthis Bidentataes 14 gram Rhizoma Atractylodis Macrocephalaes 14 gram Poria 38 grams
Pericarpium Citri Reticulatae 10.5 gram Caulis Bambusae In Taenia 11.5 gram Radix Angelicae Sinensis 13.5 gram Rhizoma Acori Graminei 9 grams
Preparation method: formulation method is made powder routinely.
Embodiment 3:
The Radix Astragali 34 gram Hirudos 5 gram Scorpios 2.5 gram Rhizoma Chuanxiongs 11.5 grams
The Fructus Corni 6.5 gram Radix Achyranthis Bidentataes 14 gram Rhizoma Atractylodis Macrocephalaes 7 gram Poria 37 grams
Pericarpium Citri Reticulatae 6.5 gram Caulis Bambusae In Taenia 11 gram Radix Angelicae Sinensis 7 gram Rhizoma Acori Graminei 8.5 grams
Preparation method: formulation method is made capsule routinely.
Embodiment 4:
The Radix Astragali 40 gram Hirudos 3.5 gram Scorpios 3.5 gram Rhizoma Chuanxiongs 9 grams
The Fructus Corni 9 gram Radix Achyranthis Bidentataes 10.5 gram Rhizoma Atractylodis Macrocephalaes 10 gram Poria 25 grams
Pericarpium Citri Reticulatae 9 gram Caulis Bambusae In Taenia 9 gram Radix Angelicae Sinensis 10.5 gram Rhizoma Acori Graminei 7.5 grams
Preparation method: formulation method is made pill routinely.
Embodiment 5:
The Radix Astragali 48 gram Hirudos 2.5 gram Scorpios 4.5 gram Rhizoma Chuanxiongs 7 grams
The Fructus Corni 11 gram Radix Achyranthis Bidentataes 7 gram Rhizoma Atractylodis Macrocephalaes 14 gram Poria 15 grams
Pericarpium Citri Reticulatae 10 gram Caulis Bambusae In Taenia 7 gram Radix Angelicae Sinensis 13 gram Rhizoma Acori Graminei 5.5 grams
Preparation method: formulation method is made oral liquid routinely.
Claims (10)
1. Chinese medicine composition for the treatment of vertigo is characterized in that being being made by the crude drug of following weight portion ratio:
Radix Astragali 30-50 Hirudo 2-5 Scorpio 2-5 Rhizoma Chuanxiong 6-12
Fructus Corni 6-12 Radix Achyranthis Bidentatae 6-15 Rhizoma Atractylodis Macrocephalae 6-15 Poria 12-40
Pericarpium Citri Reticulatae 6-12 Caulis Bambusae In Taenia 6-12 Radix Angelicae Sinensis 6-15 Rhizoma Acori Graminei 5-10.
2, the Chinese medicine composition of treatment vertigo according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Radix Astragali 35-45 Hirudo 2-5 Scorpio 2-5 Rhizoma Chuanxiong 7-10
Fructus Corni 7-10 Radix Achyranthis Bidentatae 8-13 Rhizoma Atractylodis Macrocephalae 8-14 Poria 18-35
Pericarpium Citri Reticulatae 7-11 Caulis Bambusae In Taenia 6-12 Radix Angelicae Sinensis 6-13 Rhizoma Acori Graminei 5-10.
3, the Chinese medicine composition of treatment vertigo according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
The Radix Astragali 32 Hirudos 2.5 Scorpios 2.5 Rhizoma Chuanxiongs 7
Fructus Corni 7 Radix Achyranthis Bidentataes 7 Rhizoma Atractylodis Macrocephalaes 7 Poria 15
Pericarpium Citri Reticulatae 6.5 Caulis Bambusae In Taenia 6.5 Radix Angelicae Sinensis 7 Rhizoma Acori Graminei 6.
4, the Chinese medicine composition of treatment vertigo according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
The Radix Astragali 48 Hirudos 4.5 Scorpios 4.5 Rhizoma Chuanxiongs 11
Fructus Corni 11 Radix Achyranthis Bidentataes 14 Rhizoma Atractylodis Macrocephalaes 14 Poria 38
Pericarpium Citri Reticulatae 10.5 Caulis Bambusae In Taenia 11.5 Radix Angelicae Sinensis 13.5 Rhizoma Acori Graminei 9.
5, the Chinese medicine composition of treatment vertigo according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
The Radix Astragali 34 Hirudos 5 Scorpios 2.5 Rhizoma Chuanxiongs 11.5
Fructus Corni 6.5 Radix Achyranthis Bidentataes 14 Rhizoma Atractylodis Macrocephalaes 7 Poria 37
Pericarpium Citri Reticulatae 6.5 Caulis Bambusae In Taenia 11 Radix Angelicae Sinensis 7 Rhizoma Acori Graminei 8.5
6, the Chinese medicine composition of treatment vertigo according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
The Radix Astragali 40 Hirudos 3.5 Scorpios 3.5 Rhizoma Chuanxiongs 9
Fructus Corni 9 Radix Achyranthis Bidentataes 10.5 Rhizoma Atractylodis Macrocephalaes 10 Poria 25
Pericarpium Citri Reticulatae 9 Caulis Bambusae In Taenia 9 Radix Angelicae Sinensis 10.5 Rhizoma Acori Graminei 7.5.
7, according to each described Chinese medicine composition of claim 1-6, the preparation formulation that it is characterized in that this Chinese medicine composition is decoction, powder, capsule, pill or oral liquid.
8,, it is characterized in that described vertigo is a megrim caused by vertebra-fundus artery blood supply insufficiency as the Chinese medicine composition of each described treatment vertigo of claim 1-6.
9,, it is characterized in that described vertigo is the cervical vertigo that circulatory disturbance causes according to the Chinese medicine composition of the arbitrary described treatment vertigo of claim 1-6.
10,, it is characterized in that described vertigo is the aural vertigo that circulatory disturbance causes according to the Chinese medicine composition of the arbitrary described treatment vertigo of claim 1-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101632070A CN101411829A (en) | 2007-10-19 | 2007-10-19 | Chinese medicinal composition for treating megrims and formulation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101632070A CN101411829A (en) | 2007-10-19 | 2007-10-19 | Chinese medicinal composition for treating megrims and formulation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101411829A true CN101411829A (en) | 2009-04-22 |
Family
ID=40592707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101632070A Pending CN101411829A (en) | 2007-10-19 | 2007-10-19 | Chinese medicinal composition for treating megrims and formulation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101411829A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869674A (en) * | 2010-06-01 | 2010-10-27 | 张晓玲 | Chinese medicinal composition for treating vertigo |
| CN102772675A (en) * | 2012-07-24 | 2012-11-14 | 重庆希尔安药业有限公司 | Pharmaceutical composition for treating apoplexy hemiplegia and preparation method of pharmaceutical composition |
| CN102772676A (en) * | 2012-08-20 | 2012-11-14 | 解连新 | Traditional Chinese medicine for treating empirical vertigo |
| CN104887964A (en) * | 2015-06-02 | 2015-09-09 | 张永伟 | Traditional Chinese medicine for treating phlegm-accumulation vein-resistance type vertigo and preparation method of traditional Chinese medicine |
| CN107019768A (en) * | 2017-05-28 | 2017-08-08 | 成都风靡生物科技有限公司 | It is a kind of effectively to treat capsule medicine of vertigo and preparation method thereof |
| CN108434385A (en) * | 2018-05-18 | 2018-08-24 | 重庆跃龙生物制药有限公司 | Chinese medicine composition and preparation method thereof for treating vertigo |
-
2007
- 2007-10-19 CN CNA2007101632070A patent/CN101411829A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869674A (en) * | 2010-06-01 | 2010-10-27 | 张晓玲 | Chinese medicinal composition for treating vertigo |
| CN101869674B (en) * | 2010-06-01 | 2012-07-04 | 张晓玲 | Chinese medicinal composition for treating vertigo |
| CN102772675A (en) * | 2012-07-24 | 2012-11-14 | 重庆希尔安药业有限公司 | Pharmaceutical composition for treating apoplexy hemiplegia and preparation method of pharmaceutical composition |
| CN102772675B (en) * | 2012-07-24 | 2013-12-11 | 重庆希尔安药业有限公司 | Pharmaceutical composition for treating apoplexy hemiplegia and preparation method of pharmaceutical composition |
| CN102772676A (en) * | 2012-08-20 | 2012-11-14 | 解连新 | Traditional Chinese medicine for treating empirical vertigo |
| CN102772676B (en) * | 2012-08-20 | 2014-04-16 | 济南伟传信息技术有限公司 | Traditional Chinese medicine for treating empirical vertigo |
| CN104887964A (en) * | 2015-06-02 | 2015-09-09 | 张永伟 | Traditional Chinese medicine for treating phlegm-accumulation vein-resistance type vertigo and preparation method of traditional Chinese medicine |
| CN107019768A (en) * | 2017-05-28 | 2017-08-08 | 成都风靡生物科技有限公司 | It is a kind of effectively to treat capsule medicine of vertigo and preparation method thereof |
| CN108434385A (en) * | 2018-05-18 | 2018-08-24 | 重庆跃龙生物制药有限公司 | Chinese medicine composition and preparation method thereof for treating vertigo |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103845642B (en) | A kind of compositions of heat-clearing and toxic substances removing removing heat from blood U.S. face | |
| CN101411829A (en) | Chinese medicinal composition for treating megrims and formulation thereof | |
| CN102078487B (en) | Chinese medicinal preparation for treating vertigo | |
| CN101579186B (en) | Pharmaceutical rhinitis pillow for external use and treating wind-heat rhinitis | |
| CN101530579B (en) | A pharmaceutical composition for soothing the nerves | |
| CN100389802C (en) | Medicine for treating and preventing chronic obstractive pneumonia | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| CN101564458A (en) | Application of Chinese medicinal composition in preparing medicament for treating bronchitis | |
| CN102274385A (en) | Medicament for treating nasosinusitis and preparation method thereof | |
| CN102198181B (en) | Antithrombotic and thrombosis-eliminating preparation | |
| CN104825563B (en) | A kind of Chinese medicine preparation treating cervical spondylosis and preparation method thereof | |
| CN101869653B (en) | Chinese medicinal preparation for treating chronic nasosinusitis and preparation method thereof | |
| CN102145050A (en) | Application of traditional Chinese medicine composition for preparing drugs for preventing and treating post percutaneous coronary intervention (PCI) no-reflow | |
| CN103565929A (en) | Traditional Chinese medicine combination for treating heart blood deficiency type night sweat | |
| CN103230566A (en) | Traditional Chinese medical composition for treating cholecystitis cholelithiasis and application thereof | |
| CN102327451B (en) | Chinese medicinal composition for treating chronic sinusitis | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN107929338A (en) | The new application of Pien Tze Huang and its preparation in the medicine for preparing treatment post-herpetic neuralgia | |
| CN101559161B (en) | Application of traditional Chinese medicine composition in preparing medicament for curing tristimania | |
| CN104857414A (en) | Medicine composite for treating chronic simple rhinitis | |
| CN102416147B (en) | Medicinal composition for treating mania of patients abstained from drugs | |
| CN101385836B (en) | Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof | |
| CN1857533A (en) | Chinese medicine preparation for preventing and treating cerebral thrombus and its sequel | |
| CN101683459B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating sleep disorder | |
| CN105232995A (en) | Traditional Chinese medicine treating facial paralysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090422 |